The United Kingdom and the United States have established a key trade agreement that will guarantee no duties on British medicine exports going into the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This pledge guarantees that import taxes on these key exports will remain at nothing for a timeframe of the next three years.
This agreement comes after earlier statements to significantly raise duties on branded pharmaceutical products, with potential rates mentioned reaching 100%.
"This agreement with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and introduces much-needed balance to American-British pharmaceutical trade," a release said.
Commercial Impact
Medicines represent one of the UK's most significant exports to the United States, which is by far the largest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to the third quarter, the UK sold pharmaceutical products worth billions to the US. This amount represented nearly one-fifth of British export trade in that timeframe.
"This guarantee secures employment, stimulates capital expenditure and paves the way for the UK to become a international leader for medical research," a minister stated.
Key NHS Changes
The agreement involves several specific commitments from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments topped twenty percent.
Industry Background
This agreement comes amid a protracted row between the sector and the ministers over spending levels and approval rates.
This friction were exacerbated by assertions that American patients were paying a premium for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or cancelled, while substantial expansions have been announced toward projects in the United States.
One official acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the past decade.
